

AMENDMENTS TO THE CLAIMS

Claims 1-8 (cancelled).

Claim 9 (currently amended). [[A]] An isolated peptide having consisting of the amino acid residue sequence CILGSDGEKNQCVTGEGTPKPESHNDGDFE (SEQ ID NO: 1) or a ~~sequence~~ portion of SEQ ID NO: 1 consisting of at least 9 consecutive amino acid residues of SEQ ID NO: 1, and having a potential MHC class II binding activity, wherein said peptide has a stimulation index of > 1.8 in a biological assay of cellular proliferation and said index is taken as the value of cellular proliferation scored following stimulation by the peptide and divided by the value of cellular proliferation scored in control cells not in receipt of the peptide.

Claims 10-16 (cancelled).

Claim 17 (new). A pharmaceutical composition comprising the peptide of claim 9, optionally together with a pharmaceutically acceptable carrier, diluent or excipient.